Medication Risk in Private Health Insurance Claims

Reduce medication-related complexity and improve member outcomes through specialist pharmacy review

Published: 3 April 2026 | Updated: 3 April 2026

The Medication Risk Challenge in Private Health Insurance

Private health insurance members often have complex medical histories and multi-medication regimes. Their claims can involve high-cost treatment, specialist services, and uncertain outcomes. Medication management sits at the centre of member experience and claim complexity. Yet PHI claim managers often lack visibility into medication appropriateness, interactions, and risk.

Your claims team works from medical records and treatment summaries. You don't see the pharmacy-level detail: whether medications are evidence-based, whether combinations are safe, whether side effects are limiting recovery, whether deprescribing could improve outcomes and reduce treatment costs. You need specialist pharmacy insight. IMM's pharmacist-led medication reviews provide independent assessment of medication risk in your PHI claims, supporting both member outcomes and claims management efficiency.

Medication Risk Categories in PHI Claims

Drug-Drug Interactions and Safety Risk

PHI members often see multiple specialists across different care settings. Medication coordination falls between them. We screen for interactions between medications from different prescribers that may worsen disease, create new medical problems, or cause adverse events. Complex medication regimes create exponential interaction risk.

Medication Appropriateness and Evidence Alignment

Specialist prescribing sometimes includes expensive or newer agents before evidence support is established. We assess whether medications align with published evidence, therapeutic guidelines, and best practice. We identify expensive medications where evidence-based alternatives exist.

Medication-Related Adverse Events and Complications

Medications often cause harm, sometimes severe. Sedating agents cause falls; anticholinergics cause delirium; NSAIDs cause renal dysfunction. We identify medication-related complications that may be contributing to ongoing medical problems, requiring additional treatment, or preventing recovery.

Over-Treatment and Unnecessary Medications

Medications prescribed for acute conditions often persist inappropriately. We identify medications that are no longer necessary or have been supplanted by better alternatives. Reducing unnecessary medications improves safety, reduces cost, and simplifies member management.

Medication-Driven Claims Complexity

Medication side effects and interactions often drive ongoing medical problems and specialist referrals. We identify whether current claims complexity is driven by medication burden that could be reduced, potentially simplifying treatment and reducing cost.

How Pharmacy Review Reduces PHI Claims Risk

Real-World Example: PHI Claims Complexity

Situation: A 67-year-old PHI member with multiple chronic conditions (hypertension, diabetes, arthritis, depression, anxiety) has undergone orthopedic surgery for joint replacement. Post-surgery recovery is stalling; the member reports ongoing pain, poor sleep, fatigue, and mood deterioration. Current medications: atenolol, lisinopril, amlodipine, metformin, atorvastatin, celecoxib, oxycodone, pregabalin, duloxetine, sertraline, and temazepam. Specialist reviews are ongoing but progress is slow.

IMM Review Findings: Medication regime is contributing significantly to recovery stalling. Atenolol, amlodipine, and lisinopril triple cardiac therapy is excessive for this member's blood pressure control; is causing fatigue. Oxycodone and pregabalin combined exceed evidence recommendations and are causing sedation, fatigue, and poor sleep (paradoxical insomnia at night, daytime sedation). Duloxetine and sertraline both treat depression; combination is excessive. Temazepam for sleep is counterproductive; long-term benzodiazepines disrupt sleep architecture and cause dependence. Celecoxib at high dose is appropriate for arthritis but NSAIDs delay orthopedic healing; dose reduction or cessation would support post-operative recovery.

Outcome: Medication review recommendations: reduce cardiac medication burden (adjust beta-blocker and calcium channel antagonist), reduce oxycodone and pregabalin, cease temazepam with taper support, reduce celecoxib, continue either duloxetine or sertraline (not both). Within six weeks of implementation, member reports improved energy, sustained pain relief, better sleep, and improved mood. Post-surgical recovery accelerates. Specialist involvement requirements decrease. Member achieves mobility and independence goals faster. Improved outcomes, reduced specialist costs, simplified ongoing management.

Common PHI Claims Scenarios Requiring Medication Review

Post-surgical recovery complications: Medications prescribed for pain and anxiety often slow healing and recovery. Review identifies medication adjustments that could accelerate surgical recovery and return to function.

Specialist coordination gaps: Multiple specialists prescribe without coordinating. Review identifies medication redundancies, interactions, and coordination opportunities that improve safety and simplify management.

Chronic disease management plateau: Medical treatments plateau despite escalating medication regimes. Review identifies whether medication side effects or inadequate deprescribing are creating barriers to improvement.

Mental health comorbidity: Anxiety and depression complicate physical illness treatment. Review assesses whether mental health medications are appropriate, well-dosed, and whether medication combinations are safe and effective.

Medication cost management: Expensive specialist-prescribed medications may have evidence-based alternatives. Review identifies cost optimisation opportunities without compromising member outcomes.

Medication Review Integration Into PHI Process

For claims teams: Identify high-cost, complex, or stalled claims. Request pharmacy review to assess medication risk, identify deprescribing opportunities, and support treatment planning.

For member communication: Use medication review findings to inform member discussions about medication safety and optimization. Transparent medication assessment builds member trust and supports engagement with treatment changes.

For provider coordination: Share IMM's recommendations with treating specialists and GPs to support coordinated medication optimization. Pharmacy review provides common ground for specialist discussion.